GLOSTRUP, DENMARK--(Marketwire - February 12, 2013) - Dako, an Agilent Technologies company,
announced today it has entered into a collaboration agreement with Pfizer
field of companion diagnostics.
The agreement constitutes a legal framework for various collaboration
between the two companies, covering research, development and
as well as advisory services.
"We are extremely excited to partner with Pfizer, a company with such a
presence and reputation for market leadership," said Lars Holmkvist, CEO of
and senior vice president, Agilent. "This collaboration is testimony to
level of expertise and service Dako is committed to delivering to our
in companion diagnostics."
Companion diagnostics are seen as the cornerstones of precision medicine.
provide a way to improve patient care and reduce health-care costs by
specific therapies to the individuals most likely to benefit from them,
all patients do not respond in the same way.
"This partnership with Dako will support Pfizer's companion diagnostics
an important component of our growing Precision Medicine capabilities,"
John Hubbard, senior vice president, Development Operations at Pfizer.
"Precision Medicine R&D is designed to advance more targeted therapies for
patients, improve efficacy, safety and success rates, and expedite
Financial terms of the agreement were not disclosed.
Today's news follows an earlier announcement from Dako introducing a master
framework agreement between Dako and Eli Lilly and Company, which focuses
developing novel companion diagnostics for Eli Lilly's oncology pipeline.
About Dako - An Agilent Technologies Company
Dako is relentless in its commitment to fighting cancer together with
and strategic partners-because patients' lives depend on companies
bring scientific advancement to the diagnostic and therapeutic fields.
Dako, based in Denmark, is a global leader in tissue-based cancer
Hospital and research laboratories worldwide use Dako's reagents,
software and expertise to make accurate diagnoses and determine the most
effective treatment for cancer patients. Dako, with 1,200 employees,
more than 100 countries. Dako became part of Agilent Technologies on June
21, 2012. Information about Dako is available at www.dako.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is the world's premier measurement
and a technology leader in chemical analysis, life sciences, diagnostics,
electronics and communications. The company's 20,500 employees serve
in more than 100 countries. Agilent had revenues of $6.9 billion in fiscal
2012. Information about Agilent is available at www.agilent.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Dako Denmark A/S via Thomson Reuters ONE